Trials / Withdrawn
WithdrawnNCT01423240
Major Depressive Disorder With Mixed Features
A Randomized, 6-week, Double-blind, Placebo-controlled, Fixed-dose, Parallel Group Study of Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Sumitomo Pharma America, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Lurasidone HCl is a compound that is a candidate for the treatment of major depressive with mixed features.This clinical study is designed to test how well Lurasidone works to treat major depressive disorder with mixed features.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lurasidone 20 mg | Lurasidone 20 mg once daily orally in the evening |
| DRUG | Lurasidone 60 mg | Lurasidone 60 mg once daily orally in the evening |
| DRUG | Placebo | Placebo once daily orally in the evening |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2011-08-25
- Last updated
- 2012-12-13
Locations
27 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01423240. Inclusion in this directory is not an endorsement.